세계의 신경계 질환 진단 치료 시장 : 예측(2025-2030년)

The neurological disorder diagnostics treatment market is expected to grow at a CAGR of 5.68%, reaching a market size of US$18.903 billion in 2030 from US$14.340 billion in 2025

Neurological disorders are conditions that impact the functioning of the nervous system, including the brain, spinal cord, and nerves. These disorders encompass a range of conditions, such as neurodegenerative diseases like Alzheimer's and Parkinson's disease, neuromuscular disorders like muscular dystrophy and amyotrophic lateral sclerosis, spine conditions such as spina bifida and spinal cord injuries, as well as peripheral nerve issues like peripheral neuropathy and carpal tunnel syndrome.The neurological disorder diagnostics market includes all tools, techniques, devices, products, and services used to diagnose these conditions. This encompasses technologies such as magnetic resonance imaging (MRI), computed tomography (CT), neuroimaging biomarkers, ultrasound systems, blood and cerebrospinal fluid tests for biomarkers, genetic testing, and wearable devices for data analysis. Key settings for these diagnostics include hospitals, clinics, and diagnostic centers.Several factors are driving the growth of the neurological disorder diagnostics market. The rising prevalence of neurological diseases such as Alzheimer's, dementia, and Parkinson's disease is a significant contributor. Additionally, the increasing number of brain injuries due to accidents further boosts market demand. Efforts by governments, NGOs, and institutions to raise awareness about the importance of early screening for neurological health are also propelling demand for early diagnosis. Furthermore, increased investment in research and development has led to advancements in diagnostic technologies and processes. The growing adoption of artificial intelligence (AI) and machine learning technologies enhances market growth by providing more accurate data analysis. Additionally, rising healthcare investments by governments-particularly in emerging countries-are further fueling market expansion.

Drivers of the Neurological Disorder Diagnostics Market:

• Rising Prevalence of Neurological Disorders: The global increase in neurological disorders is driven by various factors including lifestyle changes characterized by stress, mental health issues, reduced physical activity, reliance on digital technology, an aging population, and environmental pollution. These factors contribute to a surge in diseases like Alzheimer's and Parkinson's disease, thereby increasing the demand for diagnostic tools and techniques. According to data from the Alzheimer's Association, approximately 4.8 million Americans aged 65 and older have dementia due to Alzheimer's disease, with a total of 6.9 million individuals affected by dementia in the U.S.

Geographical Trends Shaping the Neurological Disorder Diagnostics Market:

• Rapid Growth in Asia-Pacific: The neurological disorder diagnostics market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is anticipated to be the fastest-growing region in this market. This growth is driven by emerging economies such as China, South Korea, and India, which are enhancing their healthcare infrastructure to address the increasing prevalence of neurological disorders.

For instance, it was estimated that around 4.8 million new cancer cases and 2.57 million cancer deaths occurred in China in 2022. This highlights the critical need for personalized medicine development through advanced diagnostic technologies.Meanwhile, North America is expected to maintain a significant share of the neurological disorder diagnostics market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this dominance; projections indicate that there will be 6.9 million dementia patients due to Alzheimer's in 2024. Additionally, government investments and private sector initiatives are driving continued regional expansion.In summary, the neurological disorder diagnostics market is experiencing robust growth driven by rising prevalence of neurological disorders globally, increased awareness about early diagnosis, technological advancements in diagnostic tools and processes, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Neurological Disorder Diagnostics Treatment Market has been segmented as following:

By Type of Disorder

• Neurodegenerative Disorders
• Neuromuscular Disorders
• Spinal Disorders
• Peripheral Nerve Disorder

By Technology

• Imaging Techniques
• In Vitro Diagnostic Techniques

By End-User

• Hospitals & Clinics
• Diagnostic Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• South Korea
• Australia
• India
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. CXO Perspective

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TYPE OF DISORDER

• 5.1. Introduction
• 5.2. Neurodegenerative Disorders
• 5.3. Neuromuscular Disorders
• 5.4. Spinal Disorders
• 5.5. Peripheral Nerve Disorder

6. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TECHNOLOGY

• 6.1. Introduction
• 6.2. Imaging Techniques
• 6.3. In Vitro Diagnostic Techniques

7. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Diagnostic Centers
• 7.4. Others

8. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Type of Disorder
  • 8.2.2. By Technology
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Type of Disorder
  • 8.3.2. By Technology
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Type of Disorder
  • 8.4.2. By Technology
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Type of Disorder
  • 8.5.2. By Technology
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Type of Disorder
  • 8.6.2. By Technology
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. South Korea
    • 8.6.4.4. Australia
    • 8.6.4.5. India
    • 8.6.4.6. Indonesia
    • 8.6.4.7. Thailand
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. GE Healthcare
• 10.2. Siemens Healthcare
• 10.3. FUJIFILM Holdings Corporation
• 10.4. Koninklijke Philips N.V.
• 10.5. Thermo Fisher Scientific Inc.
• 10.6. Masimo
• 10.7. Medtronic
• 10.8. Abbott Laboratories